The Experts below are selected from a list of 1476 Experts worldwide ranked by ideXlab platform

M A Burgess - One of the best experts on this subject based on the ideXlab platform.

  • phase ii study of vindesine and dacarbazine with or without non specific stimulation of the immune system in patients with metastatic melanoma
    European Journal of Cancer, 1993
    Co-Authors: C F Verschraegen, Evan M. Hersh, S S Legha, Carl Plager, Nicholas E Papadopoulos, M A Burgess
    Abstract:

    A single dose of dacarbazine (DTIC), followed by a 5-day intravenous infusion of vindesine (VDS) was administered every 3 weeks to 103 patients with metastatic melanoma. One half of the patients were randomised to receive intravenous Methanol Extraction Residue (MER) of bacillus Calmette-Guarin (BCG) in addition to chemotherapy, on days 7 and 14 of each course. 98 patients were evaluable. The response rates in treatment groups were 16 and 17%, respectively (confidence interval 9–24%). Neither the response rate nor the survival improved when MER was added to chemotherapy. Toxicity was moderate except for a significant granulocytopenia. The combination of DTIC and VDS is not more effective than DTIC alone and has added neurotoxicity.

C F Verschraegen - One of the best experts on this subject based on the ideXlab platform.

  • phase ii study of vindesine and dacarbazine with or without non specific stimulation of the immune system in patients with metastatic melanoma
    European Journal of Cancer, 1993
    Co-Authors: C F Verschraegen, Evan M. Hersh, S S Legha, Carl Plager, Nicholas E Papadopoulos, M A Burgess
    Abstract:

    A single dose of dacarbazine (DTIC), followed by a 5-day intravenous infusion of vindesine (VDS) was administered every 3 weeks to 103 patients with metastatic melanoma. One half of the patients were randomised to receive intravenous Methanol Extraction Residue (MER) of bacillus Calmette-Guarin (BCG) in addition to chemotherapy, on days 7 and 14 of each course. 98 patients were evaluable. The response rates in treatment groups were 16 and 17%, respectively (confidence interval 9–24%). Neither the response rate nor the survival improved when MER was added to chemotherapy. Toxicity was moderate except for a significant granulocytopenia. The combination of DTIC and VDS is not more effective than DTIC alone and has added neurotoxicity.

Evan M. Hersh - One of the best experts on this subject based on the ideXlab platform.

  • phase ii study of vindesine and dacarbazine with or without non specific stimulation of the immune system in patients with metastatic melanoma
    European Journal of Cancer, 1993
    Co-Authors: C F Verschraegen, Evan M. Hersh, S S Legha, Carl Plager, Nicholas E Papadopoulos, M A Burgess
    Abstract:

    A single dose of dacarbazine (DTIC), followed by a 5-day intravenous infusion of vindesine (VDS) was administered every 3 weeks to 103 patients with metastatic melanoma. One half of the patients were randomised to receive intravenous Methanol Extraction Residue (MER) of bacillus Calmette-Guarin (BCG) in addition to chemotherapy, on days 7 and 14 of each course. 98 patients were evaluable. The response rates in treatment groups were 16 and 17%, respectively (confidence interval 9–24%). Neither the response rate nor the survival improved when MER was added to chemotherapy. Toxicity was moderate except for a significant granulocytopenia. The combination of DTIC and VDS is not more effective than DTIC alone and has added neurotoxicity.

S S Legha - One of the best experts on this subject based on the ideXlab platform.

  • phase ii study of vindesine and dacarbazine with or without non specific stimulation of the immune system in patients with metastatic melanoma
    European Journal of Cancer, 1993
    Co-Authors: C F Verschraegen, Evan M. Hersh, S S Legha, Carl Plager, Nicholas E Papadopoulos, M A Burgess
    Abstract:

    A single dose of dacarbazine (DTIC), followed by a 5-day intravenous infusion of vindesine (VDS) was administered every 3 weeks to 103 patients with metastatic melanoma. One half of the patients were randomised to receive intravenous Methanol Extraction Residue (MER) of bacillus Calmette-Guarin (BCG) in addition to chemotherapy, on days 7 and 14 of each course. 98 patients were evaluable. The response rates in treatment groups were 16 and 17%, respectively (confidence interval 9–24%). Neither the response rate nor the survival improved when MER was added to chemotherapy. Toxicity was moderate except for a significant granulocytopenia. The combination of DTIC and VDS is not more effective than DTIC alone and has added neurotoxicity.

Carl Plager - One of the best experts on this subject based on the ideXlab platform.

  • phase ii study of vindesine and dacarbazine with or without non specific stimulation of the immune system in patients with metastatic melanoma
    European Journal of Cancer, 1993
    Co-Authors: C F Verschraegen, Evan M. Hersh, S S Legha, Carl Plager, Nicholas E Papadopoulos, M A Burgess
    Abstract:

    A single dose of dacarbazine (DTIC), followed by a 5-day intravenous infusion of vindesine (VDS) was administered every 3 weeks to 103 patients with metastatic melanoma. One half of the patients were randomised to receive intravenous Methanol Extraction Residue (MER) of bacillus Calmette-Guarin (BCG) in addition to chemotherapy, on days 7 and 14 of each course. 98 patients were evaluable. The response rates in treatment groups were 16 and 17%, respectively (confidence interval 9–24%). Neither the response rate nor the survival improved when MER was added to chemotherapy. Toxicity was moderate except for a significant granulocytopenia. The combination of DTIC and VDS is not more effective than DTIC alone and has added neurotoxicity.